LETTER TO STOCKHOLDERS AND PARTICIPATING WARRANT HOLDERS
WHO ARE RECORD HOLDERS
ACTINIUM PHARMACEUTICALS, INC.
Subscription Rights to Purchase Units
Offered Pursuant to Subscription Rights Distributed to Stockholders and Participating Warrant Holders of
Actinium Pharmaceuticals, Inc.
February 15, 2018
Dear Stockholder and Participating Warrant Holder:
This letter is being distributed by Actinium Pharmaceuticals, Inc. (the “Company”) to all holders of record of shares of its common stock, $0.001 par value per share (the “Common Stock”) and participating warrants as of 5:00 p.m., Eastern Time, on February 14, 2018 (the “Record Date”), in connection with a distribution in a rights offering (the “Rights Offering”) of non-transferable subscription rights (the “Subscription Rights”) to subscribe for and purchase units (“Units”). Each Unit entitles the holder to one share of the Company's Common Stock, 0.25 Series A Warrants, and 0.75 Series B Warrants. Each whole Series A Warrant and whole Series B Warrant will be exercisable for one share of Common Stock. The Subscription Rights and Units are described in the prospectus supplement dated February 15, 2018 (a copy of which accompanies this notice) (as it may be amended from time to time, the “Prospectus Supplement”).
Pursuant to the Rights Offering, the Company is issuing Subscription Rights to subscribe for up to 35,714,285 Units, subject to increase as described in the Prospectus Supplement, on the terms and subject to the conditions described in the Prospectus Supplement, at a subscription price of $0.70 per Unit (the “Subscription Price”).
The Subscription Rights may be exercised at any time during the subscription period, which commences on February 15, 2018 and ends at 5:00 p.m., Eastern Time, on March 2, 2018, unless extended in the sole discretion of the Company and Maxim Group LLC (as it may be extended, the “Expiration Date”).
As described in the Prospectus Supplement, holders will receive one Subscription Right for every share of Common Stock held or underlying participating warrants held owned on the Record Date, evidenced by non-transferable Subscription Rights certificates (the “Subscription Rights Certificates”). Each Subscription Right entitles the holder to purchase one Unit at the Subscription Price (the “Basic Subscription Right”).
Based on 80,072,900 shares of common stock and 21,608,333 participating warrant outstanding as of February 14, 2018, we would grant Subscription Rights to acquire 101,681,233 Units but will only accept subscriptions for 35,714,285 Units, subject to increase as described in the Prospectus Supplement. Accordingly, sufficient Units may not be available to honor your subscription in full. If exercises of Basic Subscription Rights exceed the number of Units available in the Rights Offering, we will allocate the available Units pro-rata among the record holders exercising the Basic Subscription Rights in proportion to the number of shares of our Common Stock held or underlying participating warrants held on the Record Date by each of those record holders, relative to the number of shares owned on the Record Date by all record holders exercising the Over-Subscription Privilege. If this pro-rata allocation results in any record holders receiving a greater number of Units than the record holder subscribed for pursuant to the exercise of the Basic Subscription Rights, then such record holder will be allocated only that number of Units for which the record holder subscribed, and the remaining Units will be allocated among all other record holders exercising their Basic Subscription Rights on the same pro rata basis described above. The proration process will be repeated until all Units have been allocated. If for any reason the amount of Units allocated to you is less than you have subscribed for, then the excess funds held by the Subscription Agent on your behalf will be returned to you, without interest or deduction within 10 business days after the Rights Offering has expired, and all prorating calculations and reductions contemplated by the terms of the Rights Offering have been effected, and we will have no further obligations to you.
The Company will not issue fractional shares or warrants. Fractional shares or warrants resulting from the exercise of the Basic Subscription Rights and the Over-Subscription Privileges will be eliminated by rounding down to the nearest whole Unit.
Enclosed are copies of the following documents:
|2.||Subscription Rights Certificate|
|3.||Instructions As to Use of Subscription Rights Certificates|
|4.||Notice of Important Tax Information|
|5.||A return envelope, addressed to Broadridge Corporate Issuer Solutions, Inc. (the “Subscription Agent”)|
Your prompt attention is requested. To exercise your Subscription Rights, you should deliver the properly completed and signed Subscription Rights Certificate, with payment of the Subscription Price in full for each Unit subscribed for pursuant to the Basic Subscription Right and Over-Subscription Privilege, if applicable, to the Subscription Agent, as indicated in the Prospectus Supplement. The Subscription Agent must receive the properly completed and duly executed Subscription Certificate and full payment of the Subscription Price, including final clearance of any checks, prior to the Expiration Date.
You cannot revoke the exercise of your Subscription Right. Subscription Rights not exercised at or prior to 5:00 p.m., Eastern Time, on the Expiration Date will expire.
ANY QUESTIONS OR REQUESTS FOR ASSISTANCE CONCERNING THE RIGHTS OFFERING SHOULD BE DIRECTED TO BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., THE INFORMATION AGENT, TOLL-FREE AT (855) 793-5068.